Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Chief Operating Officer | January 04, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date January 04, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2033-01-03 | Direct | 115,000 |
Reported balance
After 2023-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-04 · Grant · Acquired 115,000 · Balance 115,000 F1: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2023 Filed Jan 5, 2023 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001209191-23-001759 · doc4.xml · derivative · entry 1 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 118,750 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-002212 · doc4.xml · derivative · entry 1 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,750 Underlying: Common Stock · 118,750 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002477 · doc4.xml · derivative · entry 1 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries C-1 Preferred Stock · Derivative | 1,441 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030415 · doc4.xml · derivative · entry 4 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 3,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030415 · doc4.xml · nonDerivative · entry 1 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. Read SEC document |
| October 07, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 77,991 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0000899243-20-030415 · doc4.xml · derivative · entry 3 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,991 Underlying: Common Stock · 77,991 shares Expires 2030-10-06 F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
| June 24, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 142,983 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-20-030415 · doc4.xml · derivative · entry 2 Pedersen Anders · CIK 0001825779 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,983 Underlying: Common Stock · 142,983 shares Expires 2030-06-24 F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F3 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.